This bill amends the Controlled Substance, Drug, Device and Cosmetic Act to include new provisions regarding the scheduling and secure storage of certain controlled substances, specifically medetomidine and xylazine. It adds medetomidine to Schedule III of controlled substances, defining it as a substance with a potential for abuse that is less than those in Schedules I and II, and outlines specific conditions under which it is not considered a controlled substance. These conditions include its use in nonhuman species for approved animal drugs, manufacturing for approved animal drugs, and other authorized uses under federal or state law.

Additionally, the bill mandates that veterinarians comply with secure storage requirements for both medetomidine and xylazine, aligning with existing regulations under the Pharmacy Act. The changes aim to enhance the regulation of these substances while ensuring that their legitimate medical and veterinary uses are not hindered. The act is set to take effect immediately upon passage.

Statutes/Laws affected:
Printer's No. 1082 (Jul 24, 2025): P.L.233, No.64